MX2018002177A - Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo. - Google Patents

Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.

Info

Publication number
MX2018002177A
MX2018002177A MX2018002177A MX2018002177A MX2018002177A MX 2018002177 A MX2018002177 A MX 2018002177A MX 2018002177 A MX2018002177 A MX 2018002177A MX 2018002177 A MX2018002177 A MX 2018002177A MX 2018002177 A MX2018002177 A MX 2018002177A
Authority
MX
Mexico
Prior art keywords
same
pharmaceutical composition
catechol derivative
novel catechol
novel
Prior art date
Application number
MX2018002177A
Other languages
English (en)
Inventor
Mook Kim Hwan
Ju Kim Jung
Won Jeong Kwang
Ki Kim Sun
- Won Song Seong
Hyun Oh Seung
Original Assignee
Autophagysciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autophagysciences Inc filed Critical Autophagysciences Inc
Publication of MX2018002177A publication Critical patent/MX2018002177A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/08—Hydrogen atoms or radicals containing only hydrogen and carbon atoms
    • C07D333/10—Thiophene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

La presente invención se refiere a un compuesto representado por la Fórmula Química 1 o a una sal farmacéuticamente aceptable del mismo. El compuesto según la presente invención puede usarse de manera útil para la prevención o el tratamiento de enfermedades relacionadas con autofagia.
MX2018002177A 2015-08-21 2016-08-19 Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo. MX2018002177A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150118247A KR102100470B1 (ko) 2015-08-21 2015-08-21 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물
PCT/KR2016/009196 WO2017034242A2 (ko) 2015-08-21 2016-08-19 신규한 카테콜 유도체 및 이를 포함하는 약학적 조성물

Publications (1)

Publication Number Publication Date
MX2018002177A true MX2018002177A (es) 2018-06-06

Family

ID=58100312

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002177A MX2018002177A (es) 2015-08-21 2016-08-19 Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.

Country Status (13)

Country Link
US (2) US10662169B2 (es)
EP (1) EP3339299B1 (es)
JP (1) JP6811234B2 (es)
KR (1) KR102100470B1 (es)
CN (1) CN107922374B (es)
AU (2) AU2016312736A1 (es)
BR (1) BR112018003313A2 (es)
CA (1) CA2994377C (es)
CL (1) CL2018000420A1 (es)
ES (1) ES2865335T3 (es)
IL (1) IL257621B (es)
MX (1) MX2018002177A (es)
WO (1) WO2017034242A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7177577B2 (ja) * 2018-06-01 2022-11-24 オートファジーサイエンシーズ インコーポレイテッド 新規な化合物およびこれを含む薬学的組成物
EP3814340A4 (en) * 2018-07-20 2022-03-09 Hexapharmatec Co., Ltd. NOVEL CATECHOLD DERIVATIVES OR THEIR SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
KR20210130016A (ko) 2020-04-21 2021-10-29 (주)헥사파마텍 신규의 2-아릴티아졸 유도체 또는 이의 염, 이의 제조방법, 및 이를 함유하는 약학 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1355555A (en) * 1919-10-22 1920-10-12 Howk John Simeon Spring-controller
EP0321115B1 (en) * 1987-12-14 1991-08-14 Sawai Pharmaceutical Co., Ltd. Carboxamide derivatives having tetrazole and thiazole rings and their use
WO2005030206A1 (en) 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
WO2005079791A1 (en) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
EP1940402A4 (en) * 2005-09-20 2009-06-03 Merck & Co Inc AGONISTS OF THE NIACIN RECEPTOR, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND TREATMENT PROCEDURES
US9493419B2 (en) 2007-08-21 2016-11-15 The Hong Kong Polytechnic University Quinoline derivatives as anti-cancer agents
US9321730B2 (en) 2007-08-21 2016-04-26 The Hong Kong Polytechnic University Method of making and administering quinoline derivatives as anti-cancer agents
KR101692047B1 (ko) * 2010-11-30 2017-01-04 연세대학교 산학협력단 오토파지 관련 질환, 혈관신생질환 또는 멜라닌 관련 질환의 예방 또는 치료용 약제학적 조성물

Also Published As

Publication number Publication date
IL257621A (en) 2018-04-30
US10662169B2 (en) 2020-05-26
EP3339299B1 (en) 2021-03-03
CA2994377C (en) 2023-10-10
AU2021202309A2 (en) 2021-07-22
CA2994377A1 (en) 2017-03-02
AU2021202309B2 (en) 2022-06-23
EP3339299A2 (en) 2018-06-27
CN107922374A (zh) 2018-04-17
ES2865335T3 (es) 2021-10-15
IL257621B (en) 2021-02-28
AU2016312736A1 (en) 2018-03-08
US20200255397A1 (en) 2020-08-13
BR112018003313A2 (pt) 2018-09-18
AU2021202309A1 (en) 2021-05-13
CN107922374B (zh) 2020-11-06
EP3339299A4 (en) 2019-01-16
JP6811234B2 (ja) 2021-01-13
KR20170022790A (ko) 2017-03-02
JP2018529653A (ja) 2018-10-11
KR102100470B1 (ko) 2020-04-13
CL2018000420A1 (es) 2018-08-10
WO2017034242A3 (ko) 2017-04-20
WO2017034242A2 (ko) 2017-03-02
US20180244644A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
PH12016501750A1 (en) Human plasma kallikrein inhibitors
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
PH12018500061A1 (en) Oxysterols and methods of use thereof
SG10201811384TA (en) Mnk inhibitors and methods related thereto
TN2020000081A1 (en) Amino-methyl piperidine derivative as kinase inhibitor
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
PH12016502568A1 (en) Novel heterocyclic compound
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
MX2019012522A (es) Compuestos y metodos terapeuticos.
SG11201803867TA (en) Sodium channel blocker
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
NZ755298A (en) Pyrrolotriazine derivatives as kinase inhibitor
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
WO2018080215A8 (en) 3-AMINO ALKYLATED INDOLE DERIVATIVE, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF
NZ748746A (en) Pyrazolopyrimidine derivatives as kinase inhibitor